| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/07/2002 | CA2417204A1 Imidazolyl derivatives |
| 02/07/2002 | CA2417195A1 G-protein coupled receptors |
| 02/07/2002 | CA2417064A1 Cyclic polyamine compounds for cancer therapy |
| 02/07/2002 | CA2417059A1 3-substituted isoquinolin-1-yl derivatives |
| 02/07/2002 | CA2416978A1 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer |
| 02/07/2002 | CA2416893A1 Modified cea and uses thereof |
| 02/07/2002 | CA2416824A1 Use of an arylaldehyde 5-oxo-1, 2, 4-triazine hydrazide for the treatment of cancer |
| 02/07/2002 | CA2416788A1 Methods and pharmaceutical compositions comprising protein kinase c isoforms for healing wounds |
| 02/07/2002 | CA2415851A1 Hexahydro-7-1h-azepin-2-yl-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase |
| 02/07/2002 | CA2415826A1 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| 02/07/2002 | CA2415789A1 Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure |
| 02/07/2002 | CA2415473A1 Apo-2l receptor agonist and cpt-11 synergism |
| 02/07/2002 | CA2415436A1 Metalloproteinase-disintegrin polypeptides and methods of making and use thereof |
| 02/07/2002 | CA2415433A1 A human disintegrin protein |
| 02/07/2002 | CA2414623A1 Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis |
| 02/06/2002 | EP1178115A2 Phosphodiesterase |
| 02/06/2002 | EP1178047A1 Diazabicyclooctane derivatives and therapeutic uses thereof |
| 02/06/2002 | EP1178046A1 Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof |
| 02/06/2002 | EP1178041A1 Process for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives |
| 02/06/2002 | EP1177794A2 Composition, containing lactobacillus bulgaricus and streptococcus thermophilus, for the treatment of gastrointestinal disorders, hyperlipidemia, autoimmune diseases, and obesity |
| 02/06/2002 | EP1177792A2 Dopamine D4 Ligands for the treatment of novelty-seeking disorders |
| 02/06/2002 | EP1177791A2 Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| 02/06/2002 | EP1177445A1 Methods for screening gaba-modulatory compounds for specified pharmacological activities |
| 02/06/2002 | EP1177442A1 Determination of complex phospholipid/lipid structures using synthetic fluorescence-marked acylglycerides |
| 02/06/2002 | EP1177297A2 Novel nucleic acids and proteins with growth hormone activity |
| 02/06/2002 | EP1177296A2 Extracellular matrix and adhesion-associated proteins |
| 02/06/2002 | EP1177293A1 Growth factor homolog zvegf4 |
| 02/06/2002 | EP1177287A2 Secreted human proteins |
| 02/06/2002 | EP1177286A1 Mdm interacting protein and methods of use thereof |
| 02/06/2002 | EP1177205A1 14$g(b)-H-STEROLS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USE OF THESE DERIVATIVES FOR THE PREPARATION OF MEIOSIS REGULATING MEDICAMENTS |
| 02/06/2002 | EP1177204A2 Eplerenone crystalline form exhibiting enhanced dissolution rate |
| 02/06/2002 | EP1177200A1 Ligands for metabotropic glutamate receptors |
| 02/06/2002 | EP1177195A1 1-AMINO TRIAZOLO 4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV |
| 02/06/2002 | EP1177190A2 USE OF SELECTIVE ANTAGONISTS OF THE ALPHA 1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION |
| 02/06/2002 | EP1177186A1 Ureas and their use as cell adhesion modulators |
| 02/06/2002 | EP1177185A1 4, 5, 6, 7-tetrahydroindazole derivatives as antitumor agents |
| 02/06/2002 | EP1177178A1 Heterocyclically substituted benzimidazoles, the production and application thereof |
| 02/06/2002 | EP1177177A1 Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands |
| 02/06/2002 | EP1177176A1 Tri-aryl acid derivatives as ppar receptor ligands |
| 02/06/2002 | EP1177175A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors |
| 02/06/2002 | EP1177173A1 Hydroxamic acid derivatives as matrix metalloprotease inhibitors |
| 02/06/2002 | EP1177168A1 Caspase inhibitors and the use thereof |
| 02/06/2002 | EP1177157A1 A vital matter and a producing method |
| 02/06/2002 | EP1177016A2 Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy |
| 02/06/2002 | EP1176986A1 Differentiation of monocytes into functional dendritic cells |
| 02/06/2002 | EP1176980A1 Ccr4 antagonists in sepsis |
| 02/06/2002 | EP1176975A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| 02/06/2002 | EP1176972A1 Use of phyllanthus for targeted stimulation of the immune system |
| 02/06/2002 | EP1176971A1 Use of phyllanthus for treating chronically inflammatory and fibrotic processes |
| 02/06/2002 | EP1176968A2 Selenium-containing pro-drugs for cancer therapy |
| 02/06/2002 | EP1176967A1 Management of pain after joint surgery |
| 02/06/2002 | EP1176965A1 Antisense modulation of fas mediated signaling |
| 02/06/2002 | EP1176960A1 Synergistic combination comprising roflumilast and a pde-3 inhibitor |
| 02/06/2002 | EP1176959A1 Novel prolines as antimicrobial agents |
| 02/06/2002 | EP1176956A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| 02/06/2002 | EP1176949A2 Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same |
| 02/06/2002 | EP1176871A1 Novel beta-secretase and modulation of beta-secretase activity |
| 02/06/2002 | EP1176870A2 Tgf-alpha polypeptides, functional fragments and methods of use therefor |
| 02/06/2002 | EP0931084B1 1,3-dicarboxylic germanium complex and its therapeutic use |
| 02/06/2002 | EP0882024B1 Retroviral protease inhibiting compounds |
| 02/06/2002 | EP0863882B1 Amino substituted pyrimidines and triazines |
| 02/06/2002 | EP0843551B1 Endothelin receptor antagonists |
| 02/06/2002 | EP0836605B1 Pyrrolopyrimidines and processes for the preparation thereof |
| 02/06/2002 | EP0783490B1 1-acyl-4-aliphatic aminopiperidine compounds |
| 02/06/2002 | EP0777487B1 Treatment of stroke associated with macrophage infiltration |
| 02/06/2002 | EP0776663B1 Remedy for myotonic dystrophy |
| 02/06/2002 | EP0762888B1 Copolymer-1 improvements in compositions of copolymers |
| 02/06/2002 | EP0730448B1 Use of nitric oxide synthase substrate and/or donor, or a nitric oxide inhibitor for the manufacture of medicaments for the treatment of uterine contractility disorders |
| 02/06/2002 | EP0729354B1 Farnesyl derivatives and pharmaceutical compositions containing them |
| 02/06/2002 | EP0688219B1 Reduction of boar odor in meat |
| 02/06/2002 | EP0659082B1 Use of cytochrome p450 inhibitors for inhibiting the metabolism of nitrogen substituted acridine |
| 02/06/2002 | CN1334875A Cell signalling polypeptides and nucleic acids |
| 02/06/2002 | CN1334830A Hydrophilic ampholytic polymer |
| 02/06/2002 | CN1334820A Connective tissue growth factor fragments and methods and uses thereof |
| 02/06/2002 | CN1334819A Connective tissue growth factor fragments and methods and uses thereof |
| 02/06/2002 | CN1334813A Method for preparing (R)-(+)-3-{1-[2-(4-benzoyl-2-(3,4-difluorophenyl) morpholin-2-yl)ethyl]-4-phenylpiperdin-4-yl}-1,1-dimethylurea, its salts solvates and/or hydrates |
| 02/06/2002 | CN1334812A Piperazine derivatives |
| 02/06/2002 | CN1334811A Tricyclic farnesyl protein transferase inhibitors |
| 02/06/2002 | CN1334808A Benzamide derivs. and their use as APOB-100 secretion inhibitors |
| 02/06/2002 | CN1334806A Beta-amide and beta-sulfonamide carboxylic acid derivs., their preparation and their use as endothelin receptor antagonists |
| 02/06/2002 | CN1334804A Tetrahydroisoquinolinealkanol derivatives and pharmaceutical compositions contg. same |
| 02/06/2002 | CN1334797A 3,4-diamino-3-cyclobutene-1,2-dione derivs. which inhibit leukocyte adhesion mediated by VLA-4 |
| 02/06/2002 | CN1334743A Method for accelerating rate of mucociliary clearance |
| 02/06/2002 | CN1334740A Method for providing nutraceutical or phytoceutical benefits and inhibiting oxidation using cherry derivatives |
| 02/06/2002 | CN1334738A Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside Rb1 |
| 02/06/2002 | CN1334730A Vitronectin receptor antagonist |
| 02/06/2002 | CN1334122A Medicine for treating HIV infection, its composition and its use |
| 02/06/2002 | CN1078889C Non-pepitde tachykinin receptor antagonists |
| 02/05/2002 | US6344596 Expression of active human factor IX in mammary tissue and of milk non human transgenic mammals |
| 02/05/2002 | US6344563 Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| 02/05/2002 | US6344562 Thiazole derivatives |
| 02/05/2002 | US6344551 Contulakin-G, analogs thereof and uses therefor |
| 02/05/2002 | US6344546 A receptor protein with a cytoplasmic domain having protein kinase activity, a kinase insert, a transmembrane domain and an extracellular domain having three immunoglobulin-like repeats; for drug screening |
| 02/05/2002 | US6344486 Anticoagulants |
| 02/05/2002 | US6344483 Halogenated amidino amino acid deviratives useful as nitric oxide synthase inhibitors |
| 02/05/2002 | US6344481 Thyromimetic antiobesity agents |
| 02/05/2002 | US6344475 Cystic fibrosis |
| 02/05/2002 | US6344474 Use of central cannabinoid receptor antagonists for regulating appetence |
| 02/05/2002 | US6344471 Diisopropyl fluorophosphate (dfp), treatment of cognitive disorders, depression, schizophrenia and anxiety. |
| 02/05/2002 | US6344470 Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same |